By Sharlene George
Oncogenes such as MYC are notorious troublemakers that promote cancer. Previous research strategies have focused on finding ways to quiet down levels of MYC; however, basic scientists at Children’s Hospital of Philadelphia took the opposite approach. In preclinical models, they increased MYC activity in combination with conventional chemotherapy for Burkitt lymphoma to boost an anti-cancer response. The tumor cells became more sensitive to the drugs, and cancer cell death increased.